1. Home
  2. SEED vs INKT Comparison

SEED vs INKT Comparison

Compare SEED & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

SELL

Current Price

$0.93

Market Cap

8.5M

ML Signal

SELL

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

HOLD

Current Price

$9.41

Market Cap

59.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEED
INKT
Founded
1997
2017
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Medicinal Chemicals and Botanical Products
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
59.4M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
SEED
INKT
Price
$0.93
$9.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $39.00
AVG Volume (30 Days)
★ 37.0K
15.5K
Earning Date
05-21-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$17.65
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$8.48
52 Week High
$2.20
$15.35

Technical Indicators

Market Signals
Indicator
SEED
INKT
Relative Strength Index (RSI) 45.63 25.17
Support Level $0.66 $8.48
Resistance Level $1.08 $12.04
Average True Range (ATR) 0.12 0.55
MACD 0.00 -0.29
Stochastic Oscillator 31.71 0.28

Price Performance

Historical Comparison
SEED
INKT

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Share on Social Networks: